Patent · US Active

Antibodies directed to HER-3 and uses thereof

US11267900B2 · kind B2 · utility

0Cited by

7References

12Claims

0Family size

Assignees

DAIICHI SANKYO EUROPE GMBH · DE
AMGEN INC. · US

Inventors

Mike Rothe · San Mateo, US
Martin Treder · Heidelberg, DE
Eric Borges · Weitensfeld im Gurktal, AT
Larry Green · San Francisco, US
Susanne Hartmann · Munich, DE

Key dates

Filing date	Oct 9, 2018
Grant date	Mar 8, 2022
Priority date	—
Expiry date	Dec 31, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2800/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.